Drug
Londamocitinib clinical trials
Also written AZD4604.
- studies test it
- 6
- open now
- 0
- in phase 3
- 0
- first study started
- 2022
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2024 (3)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 3 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 0
Related medicines
As reviewed, each with the page that says it.
- One of Janus Kinase Inhibitors source
- One of Protein Kinase Inhibitors source
- One of Tyrosine Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses londamocitinib is read from its arms, and is right about nine times in ten.
Testing it · 6
- A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled AZD4604 in Healthy Japanese and Chinese Participants.CompletedPhase 1AstraZenecaNCT06519968Written as AZD4604
- Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABACompletedPhase 2AstraZenecaNCT06020014Written as AZD4604
- Phase II Study to Evaluate the Effect of AZD4604 on Airway Inflammation and Biomarkers in Adults With AsthmaCompletedPhase 2AstraZenecaNCT06435273Written as AZD4604
- Study to Evaluate the Pharmacokinetics and Pharmacodynamics of AZD4604 Given Via the Turbuhaler® Device in Adults With Mild Asthma.CompletedPhase 1AstraZenecaNCT06732882Written as AZD4604
- An ADME Study of [14C]AZD4604 and the Absolute Bioavailability of AZD4604CompletedPhase 1AstraZenecaNCT06157255Written as AZD4604 Inhalation Powder, 1 mg
- A Clinical Trial in Healthy Volunteers and Patients With Mild Asthma to Investigate a New Medicine (AZD4604) for the Treatment of AsthmaCompletedPhase 1AstraZenecaNCT04769869Written as AZD4604 for inhalation via DPI
Codes
What other systems call londamocitinib · ClinicalTrials.gg INT016933
- UNII (FDA) JAC34RRR7SLONDAMOCITINIBOne source FDA
- NCI Thesaurus C203083LondamocitinibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | JAC34RRR7S | LONDAMOCITINIB | One source FDA |
| NCI Thesaurus | C203083 | Londamocitinib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.